RBP2 Antibody

What is RBP2 and what are its primary functions in cellular physiology?

RBP2 (Retinol-binding protein 2), also known as CRBP2 or CRBP-II, is a 16 kDa cytosolic protein predominantly localized to absorptive cells of the proximal small intestine in adults. It plays several critical roles:

• Facilitates uptake of dietary retinoid

• Supports retinoid metabolism in enterocytes

• Promotes retinoid actions locally within the intestine

• Functions as a monoacylglycerol (MAG) binding protein

RBP2 accounts for approximately 0.04% of intestinal wet weight and represents roughly 1% of cytosolic protein mass in the adult jejunum . Recent research has revealed that RBP2 also binds monoacylglycerols including the endocannabinoid 2-arachidonoylglycerol (2-AG) with binding affinities comparable to retinol .

How is RBP2 tissue expression distributed, and what is its developmental regulation?

RBP2 demonstrates highly specific tissue expression patterns:

In Adult Tissues:

• Predominantly expressed in the small intestine

• Decreasing gradient of expression from jejunum to colon

• Immunohistochemistry shows greatest expression in absorptive cells near villus tips

• Proliferating cells in intestinal crypts show minimal staining

• Goblet cells do not express RBP2

• Only trace immunoreactivity detected in adult colon, liver, and eye

Developmental Expression:

• Present in neonatal tissues including liver and intestine at levels 100-fold higher than other neonatal tissues

• Some early evidence suggested low expression in adrenals, testes, and brain, though this has not been consistently confirmed

Immunohistochemical analyses have established that RBP2 is most highly expressed near the tips of the villi with decreasing expression toward the crypt base, suggesting developmental regulation along the crypt-villus axis .

How can researchers differentiate between RBP2 and KDM5A in their studies?

A critical issue in RBP2 research is the confusion between two distinct proteins that share the "RBP2" abbreviation:

When using RBP2 antibodies, researchers should:

• Verify the target specificity using molecular weight markers (16 kDa for intestinal RBP2)

• Confirm tissue expression patterns match expected distribution

• Use positive controls (small intestine for intestinal RBP2)

• Clearly specify in publications which RBP2 protein is being studied

What are the validated applications and optimal protocols for RBP2 antibodies?

RBP2 antibodies have been successfully employed in multiple applications with specific optimization parameters:

Western Blot (WB):

• Dilution range: 1:5000-1:50000

• Recommended blocking: 5% non-fat dry milk in TBST

• Expected band size: 16 kDa

• Validated samples: Human small intestine tissue, Caco-2 cells, mouse/rat small intestine

Immunohistochemistry (IHC-P):

• Dilution range: 1:50-1:500

• Antigen retrieval: Heat-mediated with EDTA buffer pH 9.0

• Counterstain: Hematoxylin

• Validated tissue: Human small intestine

Immunofluorescence (IF/ICC):

• Dilution range: 1:50-1:100

• Cell preparation: 4% paraformaldehyde fixation

• Secondary detection: Anti-rabbit IgG with fluorescent conjugate (e.g., Dylight 488)

• Validated cell lines: SW480

For optimal results with each application, researchers should perform titration experiments with their specific samples and standardize protocols based on the positive controls indicated in literature .

What controls and validation approaches are essential when working with RBP2 antibodies?

Proper validation of RBP2 antibody specificity and performance requires multiple control strategies:

Positive Controls:

• Human/mouse/rat small intestine tissue (particularly jejunum)

• Intestinal cell lines (Caco-2, SW480)

• Recombinant RBP2 protein for antibody standardization

Negative Controls:

• RBP2-knockout tissue (when available)

• Non-expressing tissues (based on published expression data)

• Primary antibody omission controls

• Isotype controls

Validation Approaches:

• Western blot verification showing single band at 16 kDa

• Immunohistochemistry showing expected villus-tip predominant staining pattern

• Blocking peptide competition to confirm specificity

• siRNA knockdown experiments in cell lines

• Cross-validation using multiple antibodies targeting different epitopes

When validating RBP2 antibodies, researchers should observe the characteristic expression gradient along the crypt-villus axis, with higher expression in mature enterocytes near the villus tips and lower expression in proliferating cells of the crypts .

What are the recommended protocols for co-localization studies involving RBP2?

Co-localization studies of RBP2 with other proteins require careful optimization:

Sample Preparation Protocol:

• Fix tissue sections in 4% paraformaldehyde

• For FFPE sections, perform heat-mediated antigen retrieval with EDTA buffer pH 9.0

• Block with 5-10% normal serum containing 0.3% Triton X-100

• Apply primary antibodies either sequentially or simultaneously:

  • Sequential approach: First apply anti-RBP2 (1:100), detect with first secondary, block, then apply second primary antibody

  • Simultaneous approach: Apply cocktail of primary antibodies from different host species

• Detect with fluorophore-conjugated secondary antibodies with distinct emission spectra

• Counterstain nuclei with DAPI

• Mount with anti-fade medium

Optimization Considerations:

• Primary antibody concentration requires titration for each antibody pair

• Sequential staining is preferred when both primary antibodies are from the same species

• Confocal microscopy with sequential scanning helps minimize bleed-through artifacts

• Z-stack acquisition allows three-dimensional analysis of co-localization

Potential Co-staining Targets:

• Enzymes involved in retinoid metabolism

• MAG lipase and enzymes in monoacylglycerol pathways

• Endocannabinoid system components

• Enteroendocrine markers to assess relationships with hormone secretion

How can RBP2 antibodies be utilized to investigate its recently discovered monoacylglycerol binding function?

The discovery that RBP2 binds monoacylglycerols opens exciting research avenues that can be explored using antibody-based techniques:

Immunoprecipitation-Mass Spectrometry Approach:

• Use RBP2 antibodies to immunoprecipitate the protein from intestinal tissues or cell lysates

• Extract bound lipids using organic solvents

• Analyze lipid composition by LC-MS/MS to identify and quantify bound MAGs

• Compare lipid profiles across different physiological conditions

Comparative Binding Studies:
Recent research has established binding constants for RBP2 with various ligands:

• 2-AG: Kd = 27.1 ± 2.4 nM

• 2-OG: Kd = 65.4 ± 4.4 nM

• 2-LG: Kd = 40.0 ± 4.9 nM

• 1-AG: Kd = 21.0 ± 2.7 nM

• AEA: Kd = 663.0 ± 24.0 nM (much lower affinity)

X-ray crystallographic studies have confirmed that MAGs bind in the same retinol binding pocket of RBP2, suggesting a dual function for this protein in lipid metabolism. Researchers can use competitive binding assays with fluorescently labeled retinol to measure displacement by various MAGs in different experimental conditions .

What methodological approaches can be used to study RBP2's role in metabolic disorders?

Research has revealed that RBP2-deficient mice develop metabolic abnormalities including increased body weight, impaired glucose metabolism, and elevated hepatic triglyceride levels. RBP2 antibodies can be instrumental in investigating these connections:

Tissue Analysis Methods:

• Immunohistochemistry to assess changes in RBP2 expression patterns in metabolic disease models

• Quantitative Western blotting to measure protein levels across multiple tissues in disease states

• Proximity ligation assays to detect interactions with metabolic enzymes

Functional Assays:

• Immunoprecipitation of RBP2 from intestinal samples before and after fat challenge

• Analysis of bound MAGs and correlation with metabolic parameters

• Investigation of hepatic lipid accumulation patterns in relation to RBP2 expression

Enteroendocrine Connection:
RBP2-deficient mice challenged with an oil gavage show elevated mucosal levels of 2-MAGs accompanied by significantly increased blood levels of GIP (glucose-dependent insulinotropic polypeptide). Researchers can use RBP2 antibodies in combination with enteroendocrine markers to investigate this connection in metabolic disorders .

How can researchers use RBP2 antibodies to study the relationship between retinoid metabolism and endocannabinoid signaling?

The dual binding capacity of RBP2 for both retinoids and endocannabinoids presents an intriguing intersection of two important signaling pathways:

Analytical Approaches:

• Dual Immunofluorescence Staining:

  • Co-localize RBP2 with cannabinoid receptors (CB1/CB2) and retinoid receptors (RAR/RXR)

  • Assess changes in distribution patterns under different dietary or pathological conditions

• Proximity-Based Assays:

  • Use RBP2 antibodies in proximity ligation assays to detect protein-protein interactions

  • Identify novel binding partners that might differ between retinoid-bound and MAG-bound states

• Functional Impact Analysis:

  • Compare RBP2 expression with endocannabinoid levels in wild-type versus disease models

  • Correlate with measurements of retinoid signaling activity

Methodological Considerations:

• Prepare samples carefully to preserve both lipid-soluble retinoids and endocannabinoids

• Use multiple antibody-based techniques (WB, IHC, IF) for comprehensive analysis

• Include appropriate controls for both signaling pathways

• Consider time-course studies to capture dynamic interactions

What are common challenges in detecting RBP2 in different sample types, and how can they be addressed?

Researchers may encounter various challenges when detecting RBP2 across different experimental contexts:

Challenge 1: Low Signal in Non-Intestinal Tissues

• Solution: Increase protein loading (50-100 μg for non-intestinal tissues)

• Approach: Use signal enhancement systems such as biotin-streptavidin amplification

• Control: Always include intestinal tissue as positive control

Challenge 2: High Background in Immunohistochemistry

• Solution: Optimize blocking conditions (5% normal serum, 0.1-0.3% Triton X-100)

• Approach: Titrate primary antibody concentration (start with 1:500 and adjust)

• Protocol Note: Ensure complete deparaffinization and effective antigen retrieval with EDTA buffer pH 9.0

Challenge 3: Multiple Bands in Western Blot

• Solution: Verify target specificity (expected 16 kDa for intestinal RBP2)

• Approach: Include positive control (small intestine lysate) and molecular weight markers

• Protocol Note: Use 5% non-fat dry milk in TBST as blocking buffer as validated in multiple studies

Challenge 4: Poor Reproducibility Between Experiments

• Solution: Standardize tissue collection and processing methods

• Approach: Implement consistent antibody handling and storage practices

• Protocol Note: Aliquot antibodies to avoid freeze-thaw cycles; store at -20°C for long-term stability

How should researchers interpret and validate unexpected RBP2 expression patterns?

When researchers encounter unexpected RBP2 expression patterns, a systematic validation approach is essential:

Validation Protocol for Unexpected Results:

• Confirm Antibody Specificity:

  • Repeat with alternative antibody targeting different epitope

  • Perform blocking peptide competition

  • Verify by multiple detection methods (WB, IHC, IF)

• Exclude Technical Artifacts:

  • Assess tissue quality and fixation consistency

  • Rule out cross-reactivity with related proteins

  • Check for non-specific binding to damaged tissues

• Consider Biological Variables:

  • Developmental stage differences

  • Pathological conditions affecting expression

  • Nutritional status (particularly vitamin A status)

  • Species-specific expression patterns

• Functional Validation:

  • Correlate expression with functional assays

  • Verify with gene expression analysis (qPCR)

  • Consider genetic approaches (siRNA, CRISPR) to confirm specificity

The published literature establishes that RBP2 is predominantly expressed in absorptive cells of the small intestine, with decreasing expression from jejunum to colon and higher expression near villus tips than crypt bases. Any deviation from this pattern requires rigorous validation .

What optimization strategies are recommended for detecting RBP2 in challenging samples or co-staining experiments?

Working with challenging samples requires specialized approaches:

For Formalin-Fixed Paraffin-Embedded (FFPE) Tissues:

• Extended antigen retrieval (20-30 minutes) with EDTA buffer pH 9.0

• Signal amplification using tyramide signal amplification (TSA)

• Automated staining platforms for consistent results

For Fresh-Frozen Tissues:

• Brief fixation (10 minutes in 4% PFA) prior to freezing

• Cryoprotection with sucrose gradient

• Careful optimization of permeabilization conditions

For Co-staining Experiments:

• Sequential Staining Protocol:

  • First primary antibody: Anti-RBP2 (1:100)

  • First detection: Goat anti-rabbit IgG-Dylight 488 (1:250)

  • Blocking step: Excess unconjugated Fab fragments

  • Second primary antibody application

  • Second detection with spectrally distinct fluorophore

• Multiplex Fluorescence Optimization:

  • Use confocal microscopy with sequential scanning

  • Implement spectral unmixing for closely overlapping fluorophores

  • Include single-stain controls for each fluorophore

For Low-Abundance Detection:

• Pre-enrichment by subcellular fractionation

• Extended antibody incubation (overnight at 4°C)

• More sensitive detection systems (Super-Signal Femto reagents)

How does RBP2 expression relate to metabolic phenotypes, and what research methods can explore this connection?

Studies have revealed unexpected metabolic phenotypes in RBP2-deficient mice:

Observed Phenotypes in RBP2-Deficient Models:

• Higher body weights by 6-7 months of age on standard chow diet

• Impaired glucose metabolism

• Increased hepatic triglyceride levels

• Similar phenotypes observed in younger mice when fed high-fat diet

• Elevated mucosal levels of 2-MAGs following oil gavage

• Significantly elevated blood levels of GIP (glucose-dependent insulinotropic polypeptide)

Research Methods to Investigate These Connections:

• Tissue-Specific Expression Analysis:

  • Quantitative immunohistochemistry across metabolic tissues

  • Western blot analysis of RBP2 levels in response to different diets

  • Correlation with metabolic parameters (glucose tolerance, insulin sensitivity)

• Functional Studies:

  • Lipid challenge tests with measurement of RBP2-bound lipids

  • Analysis of gut hormone secretion patterns in relation to RBP2 expression

  • Investigation of intestinal lipid absorption kinetics

• Translational Research Approaches:

  • Analysis of RBP2 expression in human intestinal biopsies from metabolic disease patients

  • Correlation with clinical parameters

  • Genetic association studies of RBP2 variants with metabolic traits

These findings suggest that RBP2, beyond its established role in retinoid metabolism, plays a previously unknown role in systemic energy balance through its effects on MAG metabolism and possibly enteroendocrine function .

What potential roles does RBP2 play in intestinal pathophysiology, and how can researchers investigate them?

While research on RBP2's role in intestinal pathophysiology is still emerging, several investigative approaches show promise:

Potential Pathophysiological Roles:

• Regulation of retinoid availability during intestinal inflammation/repair

• Modulation of endocannabinoid signaling affecting intestinal motility and secretion

• Impact on enterocyte lipid metabolism during disease states

• Influence on enteroendocrine function and gut hormone secretion

Research Methodologies:

• Disease Model Analysis:

  • Quantitative assessment of RBP2 expression in models of:

    • Inflammatory bowel disease

    • Intestinal ischemia-reperfusion

    • Radiation enteritis

    • Malabsorption syndromes

• Functional Interrogation:

  • RBP2 immunoprecipitation from diseased tissues followed by lipidomic analysis

  • Correlation of RBP2 levels with disease activity markers

  • Assessment of retinoid signaling activity in relation to RBP2 expression

• Mechanistic Studies:

  • Investigation of RBP2's impact on epithelial barrier function

  • Analysis of inflammatory mediator production in relation to RBP2 expression

  • Examination of intestinal stem cell dynamics and epithelial regeneration

The high expression of RBP2 in intestinal enterocytes (up to 1% of cytosolic protein) suggests it serves critical functions that may be altered during intestinal pathologies .

What are emerging research directions utilizing RBP2 antibodies in combination with advanced technologies?

The field of RBP2 research is evolving with integration of cutting-edge technologies:

Single-Cell Analysis Approaches:

• Single-cell RNA sequencing combined with RBP2 immunostaining

• Mass cytometry (CyTOF) incorporating RBP2 antibodies

• Single-cell proteomics to map RBP2 interaction networks

Advanced Imaging Technologies:

• Super-resolution microscopy for subcellular localization

• Intravital microscopy in animal models

• Label-free imaging techniques combined with immunofluorescence

Multiomic Integration:

• Correlation of RBP2 protein levels with transcriptomics data

• Integration with lipidomics to connect protein expression to lipid metabolism

• Systems biology approaches to place RBP2 in broader metabolic networks

Therapeutic Development Applications:

• Screening for compounds modulating RBP2-ligand interactions

• Development of RBP2 modulators for metabolic disorders

• Investigation of dietary interventions affecting RBP2 function

As research uncovers the broader roles of RBP2 beyond retinoid metabolism, particularly its emerging function in monoacylglycerol binding and impact on metabolic regulation, these advanced techniques will help elucidate its complex biology and potential as a therapeutic target .